Clinical Trial Update: Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating letetresgene autoleucel (lete-cel) T-cells targeting NY-ESO-1/LAGE-1a, alone or with pembrolizumab, in advanced NSCLC; the study st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• lete-cel (Letetresgene Autoleucel, GSK3377794) (lete-cel)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-08-07